Paradoxical pulmonary hemorrhage associated with hemocoagulase batroxobin in a patient with hemoptysis: A CARE-compliant case report.

Hemocoagulase, a hemostatic, is used in patients with trauma, gastrointestinal bleeding, or pulmonary hemorrhage or those undergoing surgery. However, paradoxical bleeding after hemocoagulase administration is not considered a clinically significant adverse effect. Here, we report a case of paradoxical pulmonary hemorrhage associated with hypofibrinogenemia after administration of the hemocoagulase batroxobin in a patient with hemoptysis. An 86-year-old woman complained of hemoptysis during hospitalization with organophosphate poisoning. Hemocoagulase was administered to manage bleeding; however, bleeding signs, such as hemoptysis, massive epistaxis, and ecchymosis, recurred. The patient was diagnosed with acquired hypofibrinogenemia on the basis of the reduced plasma fibrinogen level after hemocoagulase administration and lack of other causes of bleeding. Hemocoagulase administration was discontinued, and fibrinogen-containing plasma products were administered. The plasma fibrinogen level normalized and bleeding signs did not recur. It is necessary to measure plasma fibrinogen levels regularly in patients undergoing hemocoagulase administration and discontinue its administration when acquired hypofibrinogenemia is detected. Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Citation

Tae-Ok Kim, Min-Suk Kim, Bo Gun Kho, Ha Young Park, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Hong-Joon Shin. Paradoxical pulmonary hemorrhage associated with hemocoagulase batroxobin in a patient with hemoptysis: A CARE-compliant case report. Medicine. 2021 Jan 29;100(4):e24040

Mesh Tags

Substances

PMID: 33530198

search → result